Results 11 to 20 of about 24,049 (149)

Durvalumab induced immune-related agranulocytosis after conversion surgery in a patient with intrahepatic cholangiocarcinoma: a case report [PDF]

Front Immunol
Yoshihito Kitamura, Seiichi Shimizu, Shintaro Kuroda, Naruhiko Honmyo, Ryosuke Nakano, Hiroshi Sakai, Hiroyuki Tahara, Masahiro Ohira, Kentaro Ide, Tsuyoshi Kobayashi, Tatsuo Ichinohe, Hideki Ohdan   +11 more
openalex   +2 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma [PDF]

Cancers (Basel)
Piotr Kawczak, Igor Feszak, Tomasz Bączek   +2 more
openalex   +2 more sources

Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell‐Induced Ferroptosis in Ovarian Cancer

Advanced Science, EarlyView.
An integrative analysis combining in vitro genome‐wide immune screens, in vivo ICB screens, and clinical data mining identifies METTL5 as a key tumor‐intrinsic immune factor. Mechanistic studies further reveal the importance of the METTL5‐ATF4‐SLC7A11/SLC3A2‐ferroptosis axis in modulating antitumor immune responses. These findings highlight METTL5 as a
Jiakai Hou, Cheng‐Wei Ju, Nicholas A. Egan, Yanjun Wei, Yunfei Wang, Minghao Dang, Tianyi Zhou, Leilei Shi, Ningbo Zheng, Si Chen, Ashley M. Guerrero, Xiaofang Liang, Wanfu Wu, Areej Akhtar, Chitra Dhiman, Debanwita Roy Burman, Andro E. Gerges, Mason D. Flores, Han Li, Li‐Sheng Zhang, Marleen Kok, Xiaobo Mao, Linghua Wang, Qin Feng, Yiwen Chen, Sanghoon Lee, Daniel J. McGrail, Nidhi Sahni, Chuan He, Amir A. Jazaeri, Weiyi Peng   +30 more
wiley   +1 more source

EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy

Advanced Science, EarlyView.
In this study, an EGFR lipoSM PROTACs (GM‐protac), which can achieve efficient EGFR degradation and HDACi delivery, is developed. It is found that GM‐protac can both block EGFR‐dependent pathways and bypass the HDAC signaling pathway. Meanwhile, both display obvious tumor inhibition with negligible toxicity in EGFR‐TKI‐resistant lung cancer animal ...
Dongyuan Wang, Yajing Liu, Ying Chen, Chuan Dai, Wenzhu Hu, Jinyan Han, Zigang Li, Feng Yin, Yu Zhang, Chen Shi   +9 more
wiley   +1 more source

Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Gastric cancer remains a major global health burden, especially in East Asia. Recent years have brought significant advances in multimodal management, including surgery, perioperative chemotherapy, immunotherapy, and supportive care. This review summarizes key updates from 2023 to 2024, focusing on surgical innovations, perioperative systemic ...
Katsutoshi Shoda, Yoshihiko Kawaguchi, Suguru Maruyama, Daisuke Ichikawa   +3 more
wiley   +1 more source

Is Laparoscopic/Robotic Total Gastrectomy a Reasonable and Adequate Treatment for Proximal Advanced Gastric Cancer?

Annals of Gastroenterological Surgery, EarlyView.
Although the level of evidence is not high, this review indicates that laparoscopic total gastrectomy for advanced gastric cancer can be safely performed with the progress of surgical techniques, and there is little risk of worsening survival outcomes.
Takahiro Kinoshita, Masahiro Yura, Mitsumasa Yoshida, Daiki Terajima   +3 more
wiley   +1 more source

Integrating Immune Checkpoint Inhibitors With Total Neoadjuvant Therapy in Proficient Mismatch Repair Rectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
The key to unlocking ICI benefit in pMMR/MSS LARC is to convert “cold” tumors into “hot” ones through lymphocyte‐sparing SCRT and judicious chemotherapy, creating a milieu in which ICIs can act effectively. ABSTRACT The management of locally advanced rectal cancer (LARC) has evolved with the adoption of total neoadjuvant therapy (TNT), integrated ...
Yoshinori Kagawa, Jun Watanabe, Koji Ando, Caleah Kitchens, Aron Bercz, J. Joshua Smith   +5 more
wiley   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source